Amgen, Inc.

Amgen, Inc.

Amgen, Inc.

Overview
Date Founded

1980

Headquarters

One Amgen Center Drive,Thousand Oaks, CA 91320-1799

Type of Company

Public

Employees (Worldwide)

23.4K

Industries

Biotechnology
Hospitals & Patient Services

Company Description

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Contact Data
Trying to get in touch with decision makers at Amgen, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chairman & Chief Executive Officer

Executive Director & Head of Global Media Relations

Senior Vice President, Manufacturing

Executive Director

Executive Vice President & Chief Financial Officer

Executive Vice President, General Counsel & Secretary

Senior Vice President & Chief Compliance Officer

Senior Vice President & Chief Information Officer

Senior Vice President, General Manager, US General Medicine

Senior Vice President, General Manager, US Oncology Business

Paths to Amgen, Inc.
Potential Connections via
Relationship Science
You
Amgen, Inc.
Owners & Shareholders
Details Hidden

SSgA FM’s methods of analysis include quantitative, fundamental, technical, cyclical, indexing, arbitrage, charting and other strategy specific methods. They offer a broad range of strategies including: Active, Enhanced, and Passive Equity; Active & Passive Debt; Cash Management; Multi-Asset Class Solutions; Real Estate (including Direct Real Estate); Senior Loans; Managed Futures; and Private Equity. Active equity strategies include enhanced equity and active quantitative strategies. The strategies cover market-cap and style segments of the market including: large-cap core, large-cap growth, large-cap value, mid-cap, small-cap, small-cap value, all-cap, and long-short equity. They also manage long-short and long-short market neutral strategies. SSgA FM’s Active & Passive Debt strategies offers a range of investment styles from passive to active, short to long duration, tax-exempt, sovereign to high yield, and single country to global. The firm’s Cash Management strategies seek to generate current income while preserving capital and liquidity by investing in diversified portfolios of short-term securities. SSgA FM's Multi-Asset Class strategies employ an asset allocation model as means of diversification and seek to position assets among major investment categories. Their Multi Asset Class Solutions strategies employ an asset allocation model as a method of diversification that aims to position assets among major investment categories. SSgA FM’s Managed Futures strategy allocates assets using two approaches: a managed futures strategy and a fixed income strategy. The firm’s Private Equity strategies focus on rigorous partner selection, thorough evaluation of quality investment opportunities, and fundamental, research-driven research.

Details Hidden

CWGI is the investment adviser to the American Funds Group, a family of 30 funds marketed to individuals exclusively through financial advisers and other intermediaries. American Funds are also used as investment vehicles for 401ks, other retirement plans, variable annuities and 529 college savings plans. The funds have the following characteristics: (1) a long-term, value-oriented approach; (2) long-established, global research; (3) a multiple portfolio counselor system that combines teamwork with individual accountability; (4) experienced, long-tenured investment professionals; and (5) a commitment to low operating expenses, among the lowest in the fund industry. CWGI uses a Multiple Portfolio Counselor System wherein the assets of each fund are divided into smaller, more manageable portions. Research analysts typically manage a segment as well, bringing their expertise directly to bear on the fund's results and portfolio counselors are free to make their own decisions. Investment decisions are based on internal research.

Details Hidden

PRIMECAP Management aims to provide superior long-term investment results by utilizing fundamental research and bottom-up stock picking to construct portfolios. The firm looks for stocks that will outperform the market over a three to five-year horizon. PRIMECAP Management does not have a committee or small group that decides on whether or not to invest in an idea. Each portfolio manager makes an individual decision whether or not to invest in new ideas.

Recent Transactions
Details Hidden

Amgen, Inc. purchases Celgene Corp. /OTEZLA Assets from Celgene Corp.

Details Hidden

Amgen, Inc. purchases Nuevolution AB

Details Hidden

Amgen, Inc. purchases Kirin-Amgen, Inc. from Kirin Holdings Co., Ltd.

Insider Transactions
Details Hidden
Transaction Advisors
Legal Advisor

Advised onAmgen, Inc. purchases Onyx Pharmaceuticals, Inc.

Accountant

Advised onAmgen, Inc. purchases Immunex Corp.

Legal Advisor

Advised onAmgen, Inc. purchases Immunex Corp.

Legal Advisor

Advised onAmgen, Inc. purchases Onyx Pharmaceuticals, Inc.

Legal Advisor

Advised onAmgen, Inc. purchases Onyx Pharmaceuticals, Inc.

Legal Advisor

Advised onAmgen, Inc. purchases Onyx Pharmaceuticals, Inc.

Advisors & Consultants
Advisor

Partner, Chief Financial Officer at Platinum Equity Advisors LLC

Advisor

President & Managing Director at Morgan Stanley Investment Management, Inc.

Legal Advisor

Deputy Office Managing Partner at Latham & Watkins LLP

Clients

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

DaVita is a leading provider of kidney care in the United States, delivering dialysis services to patients with chronic kidney failure and end stage renal disease. As of September 30, 2012, DaVita operated or provided administrative services at 1,912 outpatient dialysis centers in 43 states in the United States, serving approximately 150,000 patients, and at 24 centers in five countries outside of the United States that serve approximately 1,000 patients.

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

Key Stats and Financials As of 2019
Market Capitalization
$129B
Total Enterprise Value
$168B
Earnings Per Share
$12.88
Revenue
$23.3B
Net Profit
$7.84B
Total Equity
$9.67B
TEVNet Income
21.47x
Debt TEV
0.18x
Enterprise Value / Sales
7.24x
Total Debt
$30.4B
EBITDAMargin
50.64%
Enterprise Value EBITDAOperating
14.25x
EBITDA
$11.8B
Five Year Compounded Annual Growth Rate Of Revenue
3.03%
Three Year Compounded Annual Growth Rate Of Revenue
0.84%
Non-Profit Donations & Grants
Political Donations
$200
2014
$200
2014
$1,000
2014
Investments
Details Hidden

Oxford Nanopore Technologies Ltd. develops proprietary technology platform for the electronic analysis of single molecules. It also develops instruments like GridIONTM and MinIONTM which are adaptable for the analysis of DNA, RNA, proteins, small molecules and other types of molecule. The firm's platform has a broad range of potential applications, including scientific research, personalized medicine, crop science and security and defense. The company was founded by Gordon Sanghera, Spike Willcocks and John Hagan Pryce Bayley in 2005 and is headquartered in Oxford, the United Kingdom.

Details Hidden

Winsor Coombs Chartered Professional Accountants provides accounting services. The company is headquartered in Mount Pear, Canada. immatics biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany.

Investors
Details Hidden

Investor Director at Fallcon Solutions Ltd.

Details Hidden

Co-Founder at Longitude Capital Management Co. LLC

Details Hidden

Executive Officer at Hong Feng Zheng Ltd.

Suppliers
Healthpeak Properties, Inc. Trusts & Funds | Irvine, CA

Healthpeak Properties, Inc. is a real estate investment trust, which invests primarily in real estate serving the healthcare industry in the United States. It acquires, develops, leases, sells, and manages healthcare real estate and provides mortgage and other financing to healthcare providers. It operates through the following business segments: Senior Housing Triple-Net, Senior Housing Operating Portfolio (SHOP), Life Science, and Medical Office. The Senior Housing Triple-Net and Operating Portfolio segments manage senior housing facilities, which include independent living, assisted living and memory care facilities, care homes, and continuing care retirement communities by utilizing triple-net leases and RIDEA structures. The Life Science segment contains laboratory and office space primarily for biotechnology, medical device and pharmaceutical companies, scientific research institutions, government agencies, and other organizations involved in the life science industry. The Medical Office segment includes pharmacies, hospital ancillary service space, and outpatient services such as diagnostic centers, rehabilitation clinics, and day-surgery operating rooms. The company was founded in March 1985 and is headquartered in Irvine, CA.

Immunogen Inc. Medical Support Services | Waltham, MA

ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded in March 1981 and is headquartered in Waltham, MA.

Harvard Bioscience, Inc. Industrial Machinery & Manufacturing | Holliston, MA

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. It operates under the geographical segments: United States, Germany, United Kingdom, and Rest of the world. It sells its products through catalog, Website, distributors, and direct sales force. The company was founded by Dr. William T. Porter in 1901 and is headquartered in Holliston, MA.

Competitors
Regeneron Pharmaceuticals, Inc. Pharmaceuticals - Tarrytown, New York

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Roche Holding AG Pharmaceuticals - Basel, Switzerland

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

Awards & Honors
Rank #130
2016
Fortune Magazine - Fortune 1000 Companies
Sponsored by Fortune Magazine
Rank #130
2016
Fortune Magazine - Fortune 500 Companies
Sponsored by Fortune Magazine
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Amgen, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Amgen, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Amgen, Inc..